Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients

Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients

This retrospective study aimed to evaluate whether anti-glycoproteins (GPs) autoantibodies can be used as predictors of response to high-dose dexamethasone combined with rituximab (DXM-RTX) in the treatment of primary immune thrombocytopenia (ITP) patients. One-hundred twenty-six ITP patients were i...

Full description

Bibliographic Details
Main Authors:	Bingjie Ding, Liu Liu, Mengjuan Li, Xuewen Song, Yuanyuan Zhang, Ao Xia, Jingyuan Liu, Hu Zhou
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Series:	Platelets
Subjects:	primary immune thrombocytopenia dexamethasone combined with rituximab therapy anti-gpib/ix autoantibodies predictor of response
Online Access:	http://dx.doi.org/10.1080/09537104.2023.2258988

Similar Items

GPIb-IX-V and platelet clearance
by: M. Edward Quach
Published: (2022-08-01)

Soy Isoflavones Inhibit Both GPIb-IX Signaling and αIIbβ3 Outside-In Signaling via 14-3-3ζ in Platelet
by: Ming Liu, et al.
Published: (2021-08-01)

GPIbα is the driving force of hepatic thrombopoietin generation
by: Danielle Karakas, et al.
Published: (2021-05-01)

The Efficacy of High-Dose Dexamethasone vs. Other Treatments for Newly Diagnosed Immune Thrombocytopenia: A Meta-Analysis
by: Qirong Xiao, et al.
Published: (2021-05-01)

The spirit of place dynamics at GPIB Immanuel and the Pancaran Kasih in Depok
by: Riajeng Sinta Damayanti, et al.
Published: (2022-04-01)

The GPIb-IX complex on platelets: insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer development and metastasis
by: Gerd Bendas, et al.
Published: (2022-04-01)

Novel antibodies against GPIbα inhibit pulmonary metastasis by affecting vWF-GPIbα interaction
by: Yingxue Qi, et al.
Published: (2018-09-01)

Rituximab treatment efficacy in a patient with systemic lupus erythematosus with severe thrombocytopenia
by: Alexandrova O.L., et al.
Published: (2018-09-01)

Rituximab Therapy for Refractory Autoimmune Thrombocytopenia in Systemic Lupus Erythematosus
by: Didem Atay, et al.
Published: (2012-03-01)

Bilateral NAION and GPIbα gene
by: Christina S. Lim, et al.
Published: (2019-01-01)

cAMP- and cGMP-elevating agents inhibit GPIbα-mediated aggregation but not GPIbα-stimulated Syk activation in human platelets
by: Stephanie Makhoul, et al.
Published: (2019-09-01)

Hemin regulates platelet clearance in hemolytic disease by binding to GPIbα
by: Man Zhao, et al.
Published: (2024-12-01)

Glycoprotein V : the unsolved GPV puzzle
by: Quentin Kimmerlin, et al.
Published: (2022-08-01)

Steroid-resistant autoimmune thrombocytopenia in systemic lupus erythematosus treated with rituximab
by: Vasudha V Sardesai, et al.
Published: (2015-01-01)

Response to rituximab in children and adults with immune thrombocytopenia (ITP)
by: Emily M. Harris, et al.
Published: (2021-08-01)

Novel antiplatelet strategies targeting VWF and GPIb
by: Nithya Prasannan, et al.
Published: (2021-01-01)

Bernard–Soulier syndrome caused by two novel heterozygous GP1BA gene mutations: a case report and literature review
by: Senlin Zhang, et al.
Published: (2024-12-01)

Clinical efficacy of two different doses of rituximab as a treatment option in adult patients with chronic immune thrombocytopenia
by: Dina G. El-Saied, et al.
Published: (2024-06-01)

The association between platelet glycoprotein-specific antibodies and response to short-term high-dose dexamethasone with prednisone maintenance treatment in adult patients with primary immune thrombocytopenia
by: Yan-Qiu Hou, et al.
Published: (2022-12-01)

Basic mechanisms of platelet receptor shedding
by: Robert K. Andrews, et al.
Published: (2017-05-01)

Comparison of Response to Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia According to the Presence of Accessory Spleen
by: Fehmi Hindilerden, et al.
Published: (2022-07-01)

Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study
by: Arthur Mageau, et al.
Published: (2023-12-01)

A comparative study to evaluate the efficacy and cost of rituximab versus dexamethasone cyclophosphamide pulse in patients of pemphigus vulgaris
by: Sudip Das, et al.
Published: (2021-01-01)

Efficacy of Dexamethasone for Acute Primary Immune Thrombocytopenia Compared to Prednisolone: A Systematic Review and Meta-analysis
by: Yasuyuki Arai, et al.
Published: (2017-07-01)

Faster IgG4 Depletion Kinetics Observed for Anti-Desmoglein 3 Autoantibodies Following Rituximab Treatment in Patients with Pemphigus Vulgaris
by: Katharina Boch, et al.
Published: (2022-12-01)

Rituximab resistance in ITP and beyond
by: Zhengrui Xiao, et al.
Published: (2023-07-01)

Comparative retrospective evaluation of efficacy of rituximab therapy with dexamethasone cyclophosphamide pulse therapy in patients of pemphigus vulgaris at a tertiary care hospital
by: Preema Sinha, et al.
Published: (2020-01-01)

Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients
by: Eman Mostafa Hamed, et al.
Published: (2023-08-01)

The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis
by: Yunjie Li, et al.
Published: (2019-08-01)

Rituximab induced acute thrombocytopenia in a patient with systemic lupus erythematosus: a case report
by: Jevon Yudhishdran, et al.
Published: (2021-07-01)

Therapeutic efficacy and clinical effectiveness of mycophenolate mofetil and dexamethasone for immune thrombocytopenia: A retrospective observational study
by: Nilesh Wasekar, et al.
Published: (2021-01-01)

Evaluation of treatment plan by three-period pulses of high-dose dexamethasone among patients with primary immune thrombocytopenia on platelet count response and adverse events: A randomized Clinical trial
by: Alireza Sadeghi, et al.
Published: (2020-01-01)

Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases
by: Fehmi Hindilerden, et al.
Published: (2017-02-01)

A Case Series and Literature Review on Zanubrutinib Therapy for the Treatment of Relapsed/Refractory Immune Thrombocytopenia
by: Bingjie Ding, et al.
Published: (2025-02-01)

Comparison of the Clinical Efficacy of Rituximab Infusion and Dexamethasone-Cyclophosphamide Pulse Therapy and Their Effect on Serum Th1, Th2, and Th17 Cytokines in Pemphigus Vulgaris–A Prospective, Nonrandomized, Comparative Pilot Study
by: Sujay Khandpur, et al.
Published: (2024-04-01)

Organizational Communication Strategies at GPIB Margo Mulya as a Tourist-Friendly Church
by: Fariszy Revta, et al.
Published: (2025-01-01)

Second‐line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records
by: Lincy S. Lal, et al.
Published: (2020-10-01)

Retrospective Evaluation of Survival and Prognostic Factors in Immune Thrombocytopenia: A Single-Center and Cross-Sectional Study
by: Gökhan Pektaş, et al.
Published: (2024-07-01)

Altas dosis de dexametasona en la trombocitopenia inmune primaria crónica High-dose dexamethasone in chronic primary immune thrombocytopenia
by: Wilfredo Roque-García, et al.
Published: (2012-12-01)

Pulsed high-dose dexamethasone modulates Th1-/Th2-chemokine imbalance in immune thrombocytopenia
by: Zongtang Liu, et al.
Published: (2016-10-01)